ReviewGene therapy2004
Gene therapy progress and prospects: cancer gene therapy using tumour suppressor genes.
Review in Gene therapy, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed.
- Opportunities in cancer gene therapy: inhibiting MDM2 and restoring p14ARF as a means to activate p53.Molecular and cellular biochemistry · 2026Review
- Genetic Medicine Approaches for Tumor Suppressor Loss: Therapeutic Replacement with Self-Amplifying RNA.Pharmaceutical research · 2026Review
- Arthropod venom peptides: Pioneering nanotechnology in cancer treatment and drug delivery.Cancer pathogenesis and therapy · 2026Review
- Magnetothermal-activated gene editing strategy for enhanced tumor cell apoptosis.Journal of nanobiotechnology · 2024Article
- Design of PD-L1-Targeted Lipid Nanoparticles to Turn on PTEN for Efficient Cancer Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Oncolytic Adenovirus, a New Treatment Strategy for Prostate Cancer.Biomedicines · 2022Review
- Gene Therapy in Cancer Treatment: Why Go Nano?Pharmaceutics · 2020Review
- [A recombinant adenovirus vector carrying murine interleukin-21 gene controls chronic HBV infection in mice].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2017Article
- Tumor suppressor NGX6 inhibits the growth and metastasis of multiple cancers.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Review
- RB1 dual role in proliferation and apoptosis: cell fate control and implications for cancer therapy.Oncotarget · 2015Review
- OPCML is frequently methylated in human colorectal cancer and its restored expression reverses EMT via downregulation of smad signaling.American journal of cancer research · 2015Article
- Chlorotoxin-conjugated nanoparticles as potential glioma-targeted drugs.Journal of neuro-oncology · 2012Review
- Restoring expression of wild-type p53 suppresses tumor growth but does not cause tumor regression in mice with a p53 missense mutation.The Journal of clinical investigation · 2011Article
- Adenoviral vector-based strategies for cancer therapy.Current drug therapy · 2009Article
- A ligand-mediated nanovector for targeted gene delivery and transfection in cancer cells.Biomaterials · 2009Article
- ONYX-411, a conditionally replicative oncolytic adenovirus, induces cell death in anaplastic thyroid carcinoma cell lines and suppresses the growth of xenograft tumors in nude mice.Cancer gene therapy · 2008Article
- Characterization of polyion complex micelles designed to address the challenges of oligonucleotide delivery.Pharmaceutical research · 2008Article
- In vivo restoration of RhoB expression leads to ovarian tumor regression.Cancer gene therapy · 2008Article
- PCR-SSCP-DNA sequencing method in detecting PTEN gene mutation and its significance in human gastric cancer.World journal of gastroenterology · 2008Article
- Novel systemic therapies for small cell lung cancer.Journal of the National Comprehensive Cancer Network : JNCCN · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Targeting tumour suppressor gene pathways is an attractive therapeutic strategy in cancer. Since the first clinical trial took place in 1996, at least 20 other trials have investigated the possibility of restoring p53 function, either alone or in combination with chemotherapy, but with limited success. Other recent clinical trials have sought to harness abnormalities in the p53 pathway to permit tumour-selective replication of adenoviral vectors such as dl1520 (Onyx-015). Other tumour suppressor genes, such as retinoblastoma (Rb) and PTEN (phosphatase, tensin homologue, deleted on chromosome 10), are the targets for imminent clinical trials, while microarray technologies are revealing multiple new genes that are potential targets for future gene therapy.
Indexed as
Identifiers
14762396What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.